MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/2643-3230.bcd-25-0323-a

Медицинская библиотека · Blood cancer discovery · 2026

A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

Darrah Justin M, Varadarajan Indumathy, Mehta Amitkumar, Saultz Jennifer N, McKinney Matthew S, Ghosh Monalisa, Gergis Usama, Krueger Andrew, Galinsky Kevin J, Bende Girish, Ramachandran Ajeetha, Sundaresan Varsha, Kasar Siddha, Hupf Bradley, Chen Sharon, Sellner Leopold, Karmali Reem

СтатьяПеревод в очереди

Аннотация

In relapsed/refractory large B-cell lymphoma (LBCL), chimeric antigen receptor (CAR)-natural killer (NK) cell therapies offer potential advantages over CAR-T-cell therapies, including off-the-shelf availability and scalable manufacturing. We performed a phase 2 study of single-dose TAK-007, a cryopreserved, cord blood-derived, off-the-shelf CD19 CAR-NK cell therapy, in 26 heavily pre-treated patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Adverse events were manageable, with limited grade 1-2 cytokine release syndrome (11.5%). Overall response rate with TAK-007 800 x106 CD19 CAR+ viable NK cells (n=14) was 60.9% (95% CI: 38.5-80.3). Median progression-free survival was 2.0 months (95% CI: 0.99-3.58) in LBCL (n=10) and 5.6 months (95% CI: 1.05-8.57) in indolent NHL (n=7) expansion cohorts. Deep molecular responses, including ctDNA-negative responses, were achieved. Not all TAK-007 products elicited clinical responses; single cell RNA-sequencing showed NK proliferating and NK-CD56dim cell enrichment in TAK-007 products eliciting/not eliciting responses, respectively, which could inform product selection.

Для цитирования: Darrah Justin M, Varadarajan Indumathy, Mehta Amitkumar, Saultz Jennifer N, McKinney Matthew S, Ghosh Monalisa, Gergis Usama, Krueger Andrew, Galinsky Kevin J, Bende Girish, Ramachandran Ajeetha, Sundaresan Varsha, Kasar Siddha, Hupf Bradley, Chen Sharon, Sellner Leopold, Karmali Reem. A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.. Blood cancer discovery. 2026. DOI: 10.1158/2643-3230.bcd-25-0323-a.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.